tetano
Editor, Senior Moderator
Clin Exp Immunol. 2017 Jun 30. doi: 10.1111/cei.13004. [Epub ahead of print]
[h=1]Protein- and Modified Vaccinia virus Ankara-based Influenza Virus Nucleoprotein Vaccines are Differentially Immunogenic in BALB/c Mice.[/h] Altenburg AF[SUP]1[/SUP], Magnusson SE[SUP]2[/SUP], Bosman F[SUP]3[/SUP], Stertman L[SUP]2[/SUP], de Vries RD[SUP]1[/SUP], Rimmelzwaan GF[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Because of the high variability of seasonal influenza viruses and the eminent threat of influenza viruses with pandemic potential, there is great interest in the development of vaccines that induce broadly protective immunity. Most likely, broadly protective influenza vaccines are based on conserved proteins, such as nucleoprotein (NP). NP is a vaccine target of interest since it has been shown to induce cross-reactive antibody and T cell responses. Here we tested and compared various NP-based vaccine preparations for their capacity to induce humoral and cellular immune responses to influenza virus NP. The immunogenicity of protein-based vaccine preparations with Matrix-M? adjuvant as well as recombinant viral vaccine vector Modified Vaccinia virus Ankara (MVA) expressing the influenza virus NP gene, with or without modifications that aim at optimization of CD8[SUP]+[/SUP] T cell responses, was addressed in BALB/c mice. Addition of Matrix-M? adjuvant to NPwt protein-based vaccines significantly improved T cell responses. Furthermore, recombinant MVA expressing the influenza virus NP induced strong antibody and CD8[SUP]+[/SUP] T cell responses, which could not be further improved by modifications of NP to increase antigen processing and presentation. This article is protected by copyright. All rights reserved.
? 2017 British Society for Immunology.
[h=4]KEYWORDS:[/h] MVA; Matrix-M?; adjuvant; immunogenicity; influenza virus; nucleoprotein; vaccine
PMID: 28665497 DOI: 10.1111/cei.13004
[h=1]Protein- and Modified Vaccinia virus Ankara-based Influenza Virus Nucleoprotein Vaccines are Differentially Immunogenic in BALB/c Mice.[/h] Altenburg AF[SUP]1[/SUP], Magnusson SE[SUP]2[/SUP], Bosman F[SUP]3[/SUP], Stertman L[SUP]2[/SUP], de Vries RD[SUP]1[/SUP], Rimmelzwaan GF[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Because of the high variability of seasonal influenza viruses and the eminent threat of influenza viruses with pandemic potential, there is great interest in the development of vaccines that induce broadly protective immunity. Most likely, broadly protective influenza vaccines are based on conserved proteins, such as nucleoprotein (NP). NP is a vaccine target of interest since it has been shown to induce cross-reactive antibody and T cell responses. Here we tested and compared various NP-based vaccine preparations for their capacity to induce humoral and cellular immune responses to influenza virus NP. The immunogenicity of protein-based vaccine preparations with Matrix-M? adjuvant as well as recombinant viral vaccine vector Modified Vaccinia virus Ankara (MVA) expressing the influenza virus NP gene, with or without modifications that aim at optimization of CD8[SUP]+[/SUP] T cell responses, was addressed in BALB/c mice. Addition of Matrix-M? adjuvant to NPwt protein-based vaccines significantly improved T cell responses. Furthermore, recombinant MVA expressing the influenza virus NP induced strong antibody and CD8[SUP]+[/SUP] T cell responses, which could not be further improved by modifications of NP to increase antigen processing and presentation. This article is protected by copyright. All rights reserved.
? 2017 British Society for Immunology.
[h=4]KEYWORDS:[/h] MVA; Matrix-M?; adjuvant; immunogenicity; influenza virus; nucleoprotein; vaccine
PMID: 28665497 DOI: 10.1111/cei.13004